Advanced search
Publication Cover
Acta Oncologica Volume 61, 2022 - Issue 9
Journal homepage
1,413
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor: Clinical Oncology

Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial

Sarah Glewisa Department of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, Australia;b Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7764-5427View further author information
ORCID Icon,
Marliese Alexandera Department of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, Australia;b Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, AustraliaView further author information
,
Senthil Lingaratnama Department of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, AustraliaView further author information
,
Benjamin Leea Department of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, AustraliaView further author information
,
Ian Campbellb Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;c Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, AustraliaView further author information
,
Mei Krishnasamyb Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;d Academic Nursing Unit, Peter MacCallum Cancer Centre, Melbourne, Australia;e VCCC Alliance, Parkville, AustraliaView further author information
,
Maarten IJzermanb Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;f Cancer Research, University of Melbourne, Parkville, Australia;g Melbourne School of Population and Global Health, Centre for Health Policy, University of Melbourne, Parkville, AustraliaView further author information
,
Mussab Fageryf Cancer Research, University of Melbourne, Parkville, AustraliaView further author information
,
Sam Harrish Department of Medical Oncology, Bendigo Health, Bendigo, AustraliaView further author information
,
Chloe Georgiouh Department of Medical Oncology, Bendigo Health, Bendigo, AustraliaView further author information
,
Craig Underhille VCCC Alliance, Parkville, Australia;i Border Medical Oncology Research Unit, Albury Wodonga Regional Cancer Centre, East Albury, Australia;j UNSW Rural Medical School, East Albury, AustraliaView further author information
,
Mark Warrenh Department of Medical Oncology, Bendigo Health, Bendigo, AustraliaView further author information
,
Robert Campbellh Department of Medical Oncology, Bendigo Health, Bendigo, AustraliaView further author information
,
Jennifer Martink School of Medicine and Public Health, University of Newcastle, Callaghan, AustraliaView further author information
,
Jeanne Tieb Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;l Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia;m Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, AustraliaView further author information
&
Michael Michaelb Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia;l Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, AustraliaView further author information
 show all
Pages 1136-1139 | Received 10 May 2022, Accepted 30 Jul 2022, Published online: 16 Aug 2022

References

  • Henricks LM, Lunenburg C, de Man FM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19(11):1459–1467.
  • Amstutz U, Henricks LM, Offer SM, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018;103(2):210–216.
  • Glewis S, Alexander M, Khabib MNH, et al. A systematic review and Meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing. Br J Cancer. 2022;127(1):126–136.
  • Páez D, Tobeña M, Fernández-Plana J, et al. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. Br J Cancer. 2019;120(2):190–195.
  • Man FMD, Goey AKL, Van Schaik RHN, et al. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57(10):1229–1254.
  • Karas S, Innocenti F. All you need to know about UGT1A1 genetic testing for patients treated with irinotecan: a practitioner-friendly guide. J Clin Oncol Oncol Pract. 2022;18(4):270–277.
  • Collins IM, Burbury K, Underhill CR. Teletrials: implementation of a new paradigm for clinical trials. Med J Aust. 2020;213(6):263–265.e1.
  • Deenen MJ, Meulendijks D, Cats A, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016;34(3):227–234.
  • Lunenburg C, Henricks LM, Dreussi E, et al. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. Eur J Cancer. 2018;104:210–218.
  • Henricks LM, van Merendonk LN, Meulendijks D, et al. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: a matched pair analysis. Int J Cancer. 2019;144(9):2347–2354.
  • Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3–9.
  • Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants c.1679T > G, c.1236G > a/HapB3, and c.1601G > a as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639–1650.
  • EORTC Quality of Life. Quality of Life of cancer patients (QLQ-C30) version 3. [cited 2020 July 20]. https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-QLQ-C30-English.pdf
  • EuroQol Research Foundation. EQ-5D-5L UserGuide, 2019. [cited 2020 July 30]. https://euroqol.org/publications/user-guides
  • Henricks LM, Lunenburg CATC, de Man FM, et al. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. Eur J Cancer. 2019;107:60–67.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.